ABSTRACT
The last decade, generally, witnessed major advancements in understanding the pathobiology of myelodysplastic syndromes (MDS) and the 5q− syndrome in particular (see chaps. 3 and 12) (1-6). For the first time, three medications for various forms of MDS were developed and approved by the Food and Drug Administration (FDA): 5-azacytidine (azacitidine), 5-aza-2′-deoxycytidine (decitabine), and lenalidomide.
